Abrocitinib After Dupilumab in Adults With Atopic Dermatitis
Researchers sought to evaluate results from adults with moderate to severe atopic dermatitis who are treated with abrocitinib after being treated with dupilumab.
Researchers sought to evaluate results from adults with moderate to severe atopic dermatitis who are treated with abrocitinib after being treated with dupilumab.
The ADvocate 1 and ADvocate 2 trials evaluated lebrikizumab as monotherapy in patients aged 12 years and older weighing at least 40kg with moderate to severe atopic dermatitis.
Important clinical considerations for clinicians treating asthma, rhinitis, and atopic dermatitis are presented.
The prevalence, incidence, and risk for acne in adolescent and adult patients with atopic dermatitis (AD) is assessed.
A real-world study on the safety and efficacy of dupilumab as a treatment for atopic dermatitis in adolescents was conducted.
Increased consumption of dietary sodium may increase the risk for atopic dermatitis.
To better standardize the symptoms and signs of diaper dermatitis, investigators reviewed the literature for all descriptive words used to define diaper dermatitis.
The safety and tolerability of ruxolitinib cream 1.5% for maximum-use in patients with atopic dermatitis is investigated.
Atopic dermatitis-like symptoms in mice found differences in ear tissue features from AD-like mice and controls.
Is atopic dermatitis linked to dementia?